EP4469045A4 - USE OF ERGOTHIONEINE TO EXTEND LIFESPAN OR IMPROVE HEALTH - Google Patents

USE OF ERGOTHIONEINE TO EXTEND LIFESPAN OR IMPROVE HEALTH

Info

Publication number
EP4469045A4
EP4469045A4 EP23746065.4A EP23746065A EP4469045A4 EP 4469045 A4 EP4469045 A4 EP 4469045A4 EP 23746065 A EP23746065 A EP 23746065A EP 4469045 A4 EP4469045 A4 EP 4469045A4
Authority
EP
European Patent Office
Prior art keywords
ergothioneine
improve health
extend lifespan
lifespan
extend
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23746065.4A
Other languages
German (de)
French (fr)
Other versions
EP4469045A1 (en
Inventor
Kylin Liao
Joseph L Evans
Qiru Fan
Shawn Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Nutrabuilding Bio Tech Co Ltd
Original Assignee
Nanjing Nutrabuilding Bio Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Nutrabuilding Bio Tech Co Ltd filed Critical Nanjing Nutrabuilding Bio Tech Co Ltd
Publication of EP4469045A1 publication Critical patent/EP4469045A1/en
Publication of EP4469045A4 publication Critical patent/EP4469045A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP23746065.4A 2022-01-27 2023-01-16 USE OF ERGOTHIONEINE TO EXTEND LIFESPAN OR IMPROVE HEALTH Pending EP4469045A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022074358 2022-01-27
PCT/CN2023/072351 WO2023143183A1 (en) 2022-01-27 2023-01-16 Use of ergothioneine for extending lifespan or improving healthspan

Publications (2)

Publication Number Publication Date
EP4469045A1 EP4469045A1 (en) 2024-12-04
EP4469045A4 true EP4469045A4 (en) 2025-11-26

Family

ID=87470544

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23746065.4A Pending EP4469045A4 (en) 2022-01-27 2023-01-16 USE OF ERGOTHIONEINE TO EXTEND LIFESPAN OR IMPROVE HEALTH

Country Status (5)

Country Link
EP (1) EP4469045A4 (en)
CN (1) CN118524837A (en)
AU (1) AU2023210881A1 (en)
CA (1) CA3249801A1 (en)
WO (1) WO2023143183A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051119A1 (en) * 2023-09-06 2025-03-13 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Approach to reduce or inhibit advanced glycation end-products

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067221A1 (en) * 2014-09-05 2016-03-10 China Medical University Use of ergothioneine for inducing activity of nrf2 in cell
WO2021158601A1 (en) * 2020-02-03 2021-08-12 Blue California Methods and compositions related to the use of ergothioneine
WO2022242711A1 (en) * 2021-05-20 2022-11-24 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Methods for ameliorating and preventing age‐related muscle degeneration
US11534426B1 (en) * 2022-01-26 2022-12-27 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Use of ergothioneine for extending lifespan or improving healthspan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103181933B (en) * 2011-12-31 2014-08-20 中国科学院天津工业生物技术研究所 Preparation method of functional oral preparation rich in erythrothioneine
MX2022001087A (en) * 2019-07-26 2022-04-07 Fundacio Inst Dinvestigacio Biomedica De Bellvitge Idibell ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF.
CN112641777B (en) * 2021-01-07 2023-02-03 山东华熙海御生物医药有限公司 Application of ergothioneine substances in preparing medicine for preventing and treating cerebral arterial thrombosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067221A1 (en) * 2014-09-05 2016-03-10 China Medical University Use of ergothioneine for inducing activity of nrf2 in cell
WO2021158601A1 (en) * 2020-02-03 2021-08-12 Blue California Methods and compositions related to the use of ergothioneine
WO2022242711A1 (en) * 2021-05-20 2022-11-24 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Methods for ameliorating and preventing age‐related muscle degeneration
US11534426B1 (en) * 2022-01-26 2022-12-27 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Use of ergothioneine for extending lifespan or improving healthspan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEELMAN ROBERT B. ET AL: "Is ergothioneine a 'longevity vitamin' limited in the American diet?", JOURNAL OF NUTRITIONAL SCIENCE, vol. 9, no. e52, 11 November 2020 (2020-11-11), GB, pages 1 - 5, XP093324146, ISSN: 2048-6790, DOI: 10.1017/jns.2020.44 *
See also references of WO2023143183A1 *

Also Published As

Publication number Publication date
EP4469045A1 (en) 2024-12-04
WO2023143183A1 (en) 2023-08-03
CN118524837A (en) 2024-08-20
CA3249801A1 (en) 2023-08-03
AU2023210881A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
EP4093513A4 (en) USE OF BIOMARKERS TO IMPROVE IMMUNOTHERAPY
EP4308128A4 (en) IMPROVED METHODS OF USE OF PSYCHEDELICS
EP4125837A4 (en) USE OF BUPROPION AND DEXTROMETHORPHANE COMBINATIONS TO TREAT NEUROLOGICAL DISEASES
EP4312802A4 (en) USE OF PARAXANTHINE TO REDUCE EXERCISE-INDUCED MENTAL FATIGUE
EP4107943A4 (en) ENCODING OF ADJACENT SUBFRAMES
EP3969113C0 (en) USE OF SUGAR OR SUGAR ALCOHOL
EP4469045A4 (en) USE OF ERGOTHIONEINE TO EXTEND LIFESPAN OR IMPROVE HEALTH
EP4226924A4 (en) USE OF PENHYCLIDINE TO TREAT OR PREVENT VISUALLY IMPAIRED EYE DISEASES
EP4360641A4 (en) USE OF MAZDUTIDE
EP4135683C0 (en) ANTIVIRAL USE OF PLEUROMUTILINS
EP4051277A4 (en) METHODS OF TREATMENT OF LEUKEMIA AND USE OF A LEUKEMIA STEM CELL SIGNATURE TO PREDICT CLINICAL SENSITIVITY TO THERAPY
EP4268522A4 (en) UL-TDOA AND DL-TDOA TO IMPROVE ACCURACY
EP4356142A4 (en) BIOMARKERS AND DRUG COMBINATIONS TO PREDICT HEART FAILURE
EP3941451A4 (en) POLAR LIPID COMPOSITIONS TO MAINTAIN OR INCREASE MOBILITY AND VITALITY
EP4397315A4 (en) COMPOSITION TO INCREASE IMMUNOGENERATION
EP4153168A4 (en) USE OF TERPENOIDS TO TREAT OR PREVENT FIBROTIC DISEASES
IL291424A (en) Use of dkk-1 inhibitors to treat cancer
EP4209579A4 (en) BIFIDOBACTERIUM TO INHIBIT THE EXPRESSION OF THE MUSCLE ATROPHY GENE
EP4426297A4 (en) USE OF PAN BET INHIBITORS
EP4349335A4 (en) USE OF 5-NITRO-8-HYDROXYQUINOLINE
EP4262870A4 (en) USE OF FIBRIN-TARGETED IMMUNOTHERAPY TO REDUCE CORONAVIRUS PATHOGENESIS
EP4181960A4 (en) SONOGENETIC STIMULATION OF CELLS EXPRESSING TRPA1
EP4363056A4 (en) USE OF TERPENOIDS TO TREAT OR PREVENT FIBROTIC DISEASES
EP4460300A4 (en) USE OF ERGOTHIONEINE TO INCREASE GLUTATHIONE LEVELS
EP3756689A4 (en) INHIBITORS OF IL-17A ACTIVITY AND USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240827

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251028

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4172 20060101AFI20251022BHEP

Ipc: A61P 39/06 20060101ALI20251022BHEP